A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants
← catalyst calendarNCT07712640 · readout in 316 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
32estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-21 | actual | When the study began enrolling |
| Primary completion | 2027-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: BGB-58067 Tablet (F-01 Formulation)
- Drug: BGB-58067 Tablet (F-02 Formulation)
Primary outcomes
what the primary-completion date above is the date OFArea under the Plasma Concentration-Time Curve from Time 0 Infinity (AUC0-inf) for BGB-58067
measured Approximately 4 Days
Area under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t last) for BGB-58067
measured Approximately 4 Days
Maximum Observed Plasma Concentration (Cmax) of BGB-58067
measured Approximately 4 Days
Time of the Maximum Observed Concentration (Tmax) for BGB-58067
measured Approximately 4 Days
Apparent Terminal Elimination Half-life (t1/2) for BGB-58067
measured Approximately 4 Days
Apparent Total Clearance from Plasma after Oral Administration (CL/F) for BGB-58067
measured Approximately 4 Days
Apparent Volume of Distribution at Steady State after Extravascular Administration (Vz/F) for BGB-58067
measured Approximately 4 Days
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed